ChromaDexCDXC
CDXC
About: ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.
Employees: 106
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 7
192% more call options, than puts
Call options by funds: $467K | Put options by funds: $160K
53% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 17
42% more capital invested
Capital invested by funds: $46.1M [Q2] → $65.5M (+$19.4M) [Q3]
17% more funds holding
Funds holding: 78 [Q2] → 91 (+13) [Q3]
1.28% more ownership
Funds ownership: 22.37% [Q2] → 23.65% (+1.28%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
31%
upside
Avg. target
$8
31%
upside
High target
$8
31%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Roth MKM Sean McGowan 14% 1-year accuracy 4 / 29 met price target | 31%upside $8 | Buy Maintained | 6 Nov 2024 |
HC Wainwright & Co. Raghuram Selvaraju 37% 1-year accuracy 118 / 316 met price target | 31%upside $8 | Buy Maintained | 4 Nov 2024 |
Financial journalist opinion
Neutral
Business Wire
2 weeks ago
ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announced that it will participate in a webcasted company presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025. The company presentation will take place at 12:00 p.m. ET on Monday, January 13, 2025. The webcast can be accessed directly at https://lytham.
Positive
Zacks Investment Research
4 weeks ago
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
Here, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025.
Positive
Zacks Investment Research
1 month ago
ChromaDex (CDXC) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, ChromaDex (CDXC) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Neutral
Business Wire
1 month ago
ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) proudly announces its inclusion on the Inc. 2024 Best in Business list in the Health Products category. Inc.'s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made an impact on their industries and society at large. This recognition underscores ChromaDex's industry-leading NAD+ research and its expanding portfolio of healthy aging products featuring Niagen® (patented nicoti.
Positive
Zacks Investment Research
1 month ago
ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?
ChromaDex (CDXC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Positive
Zacks Investment Research
2 months ago
Recent Price Trend in ChromaDex (CDXC) is Your Friend, Here's Why
ChromaDex (CDXC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Neutral
Business Wire
2 months ago
ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, announces that its flagship patented nicotinamide riboside (NR) ingredient, Niagen®, is the hero ingredient in Longevity.Technology's inaugural supplement called Longevity.Technology® LONGEVITY. Designed to support a healthier, longer life, the supplement includes Niagen, the gold standard ingredient for enhancing NAD+ level.
Positive
Zacks Investment Research
2 months ago
What Makes ChromaDex (CDXC) a Strong Momentum Stock: Buy Now?
Does ChromaDex (CDXC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Positive
Zacks Investment Research
2 months ago
5 Stocks With Recent Price Strength to Tap Wall Street Rally
Investors target stocks that are witnessing a bull run. Some of the stocks seeing price strength are CDXC, SEZL, TILE, BGC, CORT.
Neutral
Business Wire
2 months ago
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the nationwide rollout of its pharmaceutical-grade nicotinamide riboside chloride (NRC) products, Niagen® IV, now accessible at over 200 Restore Hyper Wellness locations across the United States. This represents a major milestone, making Niagen IV—a significant advancement in intravenous NAD+ therapy—more widely acc.
Charts implemented using Lightweight Charts™